Autoantibodies against type I IFNs in patients with Ph-negative myeloproliferative neoplasms
Blood
.
2022 Apr 28;139(17):2716-2720.
doi: 10.1182/blood.2021014890.
Authors
Oscar Borsani
1
,
Paul Bastard
2
3
4
5
,
Jérémie Rosain
2
3
,
Adrian Gervais
2
3
,
Emanuela Sant'Antonio
6
,
Daniele Vanni
1
,
Ilaria Carola Casetti
1
,
Daniela Pietra
7
,
Chiara Trotti
1
,
Silvia Catricalà
7
,
Virginia Valeria Ferretti
8
,
Luca Malcovati
1
7
,
Luca Arcaini
1
7
,
Jean-Laurent Casanova
2
3
4
5
9
,
Alessandro Borghesi
10
11
,
Elisa Rumi
1
7
Affiliations
1
Department of Molecular Medicine, University of Pavia, Pavia, Italy.
2
Laboratory of Human Genetics of Infectious Diseases, Necker Branch, INSERM U1163, Necker Hospital for Sick Children, Paris, France.
3
University of Paris, Imagine Institute, Paris, France.
4
St. Giles Laboratory of Human Genetics of Infectious Diseases, Rockefeller Branch, The Rockefeller University, New York, NY, USA.
5
Department of Pediatrics, Necker Hospital for Sick Children, Paris, France.
6
Division of Hematology, Azienda USL Toscana Nord Ovest, Lucca, Italy.
7
Division of Hematology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
8
Service of Clinical Epidemiology and Biostatistic, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
9
Howard Hughes Medical Institute, New York, NY, USA.
10
Neonatal Intensive Care Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy; and.
11
Fellay lab, Ecole Polytechnique Fédérale de Lausanne, Lausanne, Switzerland.
PMID:
35100354
PMCID:
PMC9047990
DOI:
10.1182/blood.2021014890
No abstract available
Publication types
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
MeSH terms
Autoantibodies
Humans
Interferon Type I*
Myeloproliferative Disorders*
Neoplasms*
Substances
Autoantibodies
Interferon Type I
Grants and funding
R01 AI088364/AI/NIAID NIH HHS/United States
R01 AI163029/AI/NIAID NIH HHS/United States
UL1 TR001866/TR/NCATS NIH HHS/United States